Tempest Therapeutics

Today we reported exciting new survival data from the ongoing global randomized Phase 1b/2 clinical study of amezalpat (TPST-1120) in randomized first-line HCC, including a stable 0.65 HR and a six-month improvement over the control arm.   We believe the data reported put amezalpat in a strong position for a successful pivotal Phase 3 study.   Learn more here: https://bit.ly/3RD7ucV

Tempest President and CEO, Stephen Brady, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 4:00 p.m. ET. Listen to the live or archived presentation here: https://bit.ly/3k4pxZd  

Tempest President and CEO, Stephen Brady, and CMO and Head of R&D, Sam Whiting MD PhD, will discuss the latest company updates in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Wednesday, May 29, 2024 at 2:00 p.m. ET. Watch the live or archived discussion here: https://bit.ly/3k4pxZd

Happy Administrative Professionals' Day! Today, we celebrate the incredible talent and dedication of our G&A teams in pursuit of bringing lifesaving drugs to cancer patients. Your contributions are invaluable. Thank you for all you do! #AdminProfessionalsDay 

Happy Administrative Professionals' Day! Today, we celebrate the incredible talent and dedication of our G&A teams in pursuit of bringing lifesaving drugs to cancer patients. Your contributions are invaluable. Thank you for all you do! #AdminProfessionalsDay 

This week we reported preclinical data at #AACR2024 demonstrating that TPST-1120 reduced tumor growth in kidney cancer as a monotherapy, as well as increased anti-cancer activity when combined with frontline chemotherapy and immunotherapy. These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022. Read more here: https://bit.ly/43OMwwH

Today we announced that the journal Cancer Research Communications published positive data from the earlier phase 1 trial of TPST-1120 in advanced solid tumors. Data published demonstrated clinical activity of TPST-1120 as a monotherapy and in combination with nivolumab.   Read more here: https://bit.ly/49jyaFv

Yesterday we presented new preclinical data at the SITC 2024 Spring Scientific meeting showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors. Learn more about the data presented and the potential of TPST-1120 to treat multiple cancer types here: https://bit.ly/3v6sjpc